

Topical Collection

Progression of Chronic Kidney Disease

Message from the Collection Editor

The progression to End-Stage Renal Disease (ESRD) is variable according to the cause of renal disease; many factors are thought to be involved. A low-protein diet, ACE inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and SGLT2 inhibitors may reduce the progression to ESRD. The early introduction of treatment is important in reducing CKD progression. Unfortunately, the diagnosis of renal insufficiency is often late. A considerable percentage of patients who receive a kidney transplant develop a renal insufficiency. Several factors may contribute to this: immunosuppressive therapy, other drugs, hypertension, recurrence of the renal disease, etc. Premature and low-weight new-borns are prone to developing kidney disease in their lives. Patients who suffer from acute kidney injury may recover but a percentage will develop CKD later in their life.

Collecting original works in a topic collection of a journal gives researchers the opportunity to learn, share ideas, and participate in collaborative studies. Original papers dealing with the definition, causes, diagnosis, evaluation, and treatment of renal disease are welcome.

Collection Editor

Dr. Silvio Maringhini

Department of Pediatrics, ISMETT, Palermo, Italy



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/110467

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).